SOMAÍ signs exclusive UK deal to launch cannabis brands

By AI, Created 9:16 PM UTC, May 26, 2026, /AGP/ – SOMAÍ has struck an exclusive partnership with IPS Pharma and Integro Clinics to bring three internationally recognized cannabis brands into the UK medical market in the coming months. The deal aims to expand patient access to differentiated cannabinoid products through a regulated supply, distribution and clinical pathway.

Why it matters: - The agreement could widen the range of medical cannabis products available to UK doctors and patients. - The partnership combines manufacturing, distribution and clinical access in one pathway, which may make product launches faster and more compliant. - The UK is emerging as one of Europe’s most important medical cannabis markets, with demand rising for high-quality cannabinoid products and reliable supply chains.

What happened: - SOMAÍ announced an exclusive partnership with IPS Pharma and Integro Clinics to introduce a portfolio of internationally recognized cannabis brands into the UK medical cannabis market. - The companies plan to launch three globally recognized cannabis brands in the UK in the coming months. - SOMAÍ said the deal supports its broader strategy of connecting global cannabis brands with regulated medical markets.

The details: - SOMAÍ is an EU-GMP-certified, vertically integrated multi-country operator focused on cannabinoid-based medicines. - IPS Pharma is a UK importer, distributor and pharmacy with infrastructure for medicinal cannabis products. - Integro Clinics is a UK online medical clinic that provides consultations for medical cannabis treatment. - The partnership is designed to create an integrated pathway for differentiated cannabinoid-based products. - The brands are expected to bring internationally established genetics, advanced inhalation technologies and new product categories to the UK medical sector. - The collaboration aims to expand access to differentiated formulations and delivery formats while maintaining pharmaceutical-grade standards across manufacturing, distribution and patient access. - SOMAÍ said the partnership fits its plan to build a global platform for cannabinoid-based medicines through EU-GMP manufacturing, strategic distribution partnerships and clinical access networks. - IPS Pharma said the goal is to improve patient access to safe, compliant and high-quality cannabinoid medicines through a structured and patient-focused approach. - More information

Between the lines: - The deal reflects a broader industry shift toward tighter coordination among manufacturers, distributors and clinicians. - The emphasis on recognized brands and advanced delivery formats suggests SOMAÍ is targeting patients and prescribers looking for more differentiated options than standard offerings. - As the UK market matures, partnerships like this may become a key way to navigate regulation while scaling access.

What’s next: - The three cannabis brands are expected to roll out in the UK medical market over the next few months. - The companies will use the combined distribution and clinic network to support the launch. - Further expansion could follow if the initial phased rollout gains traction with healthcare professionals and patients.

The bottom line: - SOMAÍ is using an exclusive UK partnership to turn global cannabis brands into a regulated medical-market launch, with IPS Pharma and Integro Clinics providing the supply and patient-access infrastructure.